Evidence map›Paper›PMID 36674914›Full record

ArticleInternational journal of molecular sciences2023

A Pathogenic Variant Reclassified to the Pseudogene

Veronica Fragoso-Ontiveros, Marcela Angelica De la Fuente-Hernandez, Vincent Gonzalez-Osnaya, Mario Gamez-Rosales, Maria Delia Perez-Montiel, David Isla-Ortiz, David Francisco Cantu-De Leon, Rosa Maria Alvarez-Gomez

Open access · goldAbstract readCase Reports
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Veronica Fragoso-OntiverosHereditary Cancer Clinic, National Cancer Institute, San Fernando 22, Sección XVI, Tlalpan, Mexico City 14070, Mexico.
Marcela Angelica De la Fuente-HernandezHereditary Cancer Clinic, National Cancer Institute, San Fernando 22, Sección XVI, Tlalpan, Mexico City 14070, Mexico.
Vincent Gonzalez-OsnayaHereditary Cancer Clinic, National Cancer Institute, San Fernando 22, Sección XVI, Tlalpan, Mexico City 14070, Mexico.
Mario Gamez-RosalesPathology Direction, National Cancer Institute, Mexico City 14080, Mexico.
Maria Delia Perez-MontielPathology Direction, National Cancer Institute, Mexico City 14080, Mexico.ORCID 0000-0002-9338-2284
David Isla-OrtizGineco-Oncology Department, National Cancer Institute, Mexico City 14080, Mexico.
David Francisco Cantu-De LeonResearch Direction, National Cancer Institute, Mexico City 14080, Mexico.
Rosa Maria Alvarez-GomezHereditary Cancer Clinic, National Cancer Institute, San Fernando 22, Sección XVI, Tlalpan, Mexico City 14070, Mexico.
Instituto Nacional de Cancerología · MX

Funding

Consejo Nacional de Ciencia y Tecnología CONACYT FOSISS SALUD-2018-02-A3-S-39248A3-S-39248
6 · The paper itself

Abstract

The PMS2 gene is involved in DNA repair by the mismatch repair pathway. Deficiencies in this mechanism have been associated with Lynch Syndrome (LS), which is characterized by a high risk for colorectal, endometrial, ovarian, breast, and other cancers. Germinal pathogenic variants of PMS2 are associated with up to 5% of all cases of LS. The prevalence is overestimated for the existence of multiple homologous pseudogenes. We report the case of a 44-year-old woman diagnosed with breast cancer at 34 years without a relevant cancer family history. The presence of pathogenic variant NM_000535.7:c.1A > T, (p.Met1Leu) in PMS2 was determined by next-generation sequencing analysis with a panel of 322 cancer-associated genes and confirmed by capillary sequencing in the patient. The variant was determined in six family members (brothers, sisters, and a son) and seven non-cancerous unrelated individuals. Analysis of the amplified region showed high homology of PMS2 with five of its pseudogenes. We determined that the variant is associated with the PMS2P1 pseudogene following sequence alignment analysis. We propose considering the variant c.1A > T, (p.Met1Leu) in PMS2 for reclassification as not hereditary cancer-related, given the impact on the diagnosis and treatment of cancer patients and families carrying this variant.

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisPseudogenesAdultDNA Mismatch RepairEndometriumFamilyFemaleHumansMaleMismatch Repair Endonuclease PMS2Mismatch Repair Endonuclease PMS2hereditary cancerLynch Syndromepathogenic variantPMS2pseudogenereclassification

Identifiers

PMID36674914
PMCPMC9864156
OpenAlexW4315649231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.